We are creating the next generation of biologic agonists for the remittive treatment of severe inflammatory and immune diseases

• Most cellular processes are controlled by interactions between protein molecules, often protein clusters with defined geometry 
• Traditional therapeutic design is ‘one target molecule – one therapeutic binding interaction’, or two-to-one for antibodies
• But most cellular processes involve the simultaneous interaction between several or many protein molecules, or coordinated clusters of receptors that enhance signaling 
• Therapeutic modalities that can present motifs for binding to multiple target partners present next-generation opportunities
• Our proprietary computational methods are creating novel protein therapeutics that engage their targets through carefully coordinated, avid binding interactions that induce potent agonist responses
• We are creating the next generation of biologic agonists for the remittive treatment of severe inflammatory and immune diseases